Literature DB >> 2875680

A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants.

D M Fisher, J I Rosen.   

Abstract

The authors used pharmacokinetic and pharmacodynamic modeling to explain the time course of neuromuscular blockade following single or multiple doses of three nondepolarizing muscle relaxants. Published and unpublished pharmacokinetic and pharmacodynamic data for 13 normal subjects were used to simulate the duration of neuromuscular blockade (time from administration of the muscle relaxant to 25% recovery of control twitch tension) following six successive doses of atracurium (150-400 micrograms/kg initially, followed by 100 micrograms/kg), vecuronium, or pancuronium (30-80 micrograms/kg initially, followed by 20 micrograms/kg). With atracurium, duration of action was similar for the second and sixth doses, regardless of the initial dose. With vecuronium (initial doses of 30-80 micrograms/kg) and pancuronium (initial doses of 30-60 micrograms/kg), duration of action was longer after the sixth dose than after the second; with larger initial doses of pancuronium (70 and 80 micrograms/kg), duration of action was similar following the second and sixth doses. The authors also determined two recovery times (time for twitch tension to recover from 5-25% and from 25-75% of control value) for varying single doses of atracurium, vecuronium, or pancuronium. When the dose of atracurium was increased from 200 to 400 micrograms/kg, neither recovery time increased. When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875680

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

1.  The current status of edrophonium: have we come "full circle"?

Authors:  A F Kopman
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

2.  Does vecuronium accumulate in the renal transplant patient?

Authors:  M A Starsnic; M E Goldberg; D E Ritter; A T Marr; M Sosis; G E Larijani
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

Review 3.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

4.  Cumulation and reversal with prolonged infusions of atracurium and vecuronium.

Authors:  R J Martineau; B St-Jean; J B Kitts; M C Curran; P Lindsay; K A Hull; D R Miller
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

5.  Pharmacodynamics of doxacurium during cardiac surgery with hypothermic cardiopulmonary bypass.

Authors:  P McDonagh; J Y Dupuis; M Curran; J Kitts; J E Wynands
Journal:  Can J Anaesth       Date:  1996-02       Impact factor: 5.063

6.  Recovery of neuromuscular function after atracurium and pancuronium maintenance of pancuronium block.

Authors:  D G Whalley; B Lewis; N M Bedocs
Journal:  Can J Anaesth       Date:  1994-01       Impact factor: 5.063

7.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

Authors:  C Beauvoir; P Peray; J P Daures; J L Peschaud; F D'Athis
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

8.  Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients.

Authors:  Shilpa Bhimasen Joshi; Ks Vasudeva Upadhyaya; M Manjuladevi
Journal:  Indian J Anaesth       Date:  2015-03

9.  Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial.

Authors:  Satyen Parida; Venkatesan Kausalya; Sandeep Kumar Mishra; Sethuramachandran Adinarayanan
Journal:  Indian J Anaesth       Date:  2017-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.